Dana-Farber Cancer Institute | Strategic Alliance Partners

Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.

Latest from Dana-Farber Cancer Institute

Dr Bellmunt on Future Directions With ctDNA-Guided Immunotherapy in Urothelial Cancer

December 03, 2025

Video

Joaquim Bellmunt, MD, PhD, discusses future research directions with ctDNA-guided immunotherapy in urothelial cancer.

Dr Jänne on the Design of the FLAURA2 Trial of Osimertinib Plus Chemotherapy in EGFR+ NSCLC

December 03, 2025

Video

Pasi A. Jänne, MD, PhD, discusses the design of the FLAURA2 trial in EGFR+ NSCLC.

Revisit Every OncLive On Air Episode From November 2025

December 02, 2025

Article

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

Dana-Farber–Led Studies in Sickle Cell Disease, Waldenström’s, Follicular and Mantle Cell Lymphomas, and MDS Presented at ASH 2025

December 01, 2025

Article

Dana-Farber Cancer Institute will present numerous presentations at ASH 2025 about studies in hematologic diseases and cancers.

Accurate Symptom Identification and Guidelines Support LEMS Screening and Diagnosis: With Jacob Sands, MD; and Shailee Shah, MD

December 01, 2025

Podcast

Drs Sands and Shah discuss LEMS symptom identification and what guidelines currently note as best practices for the diagnosis of this disease.

Dr Bellmunt on Adjuvant Atezolizumab in Patients With MIBC Who Were ctDNA+ After Initial Testing

November 28, 2025

Video

Joaquim Bellmunt, MD, PhD, discusses subgroup and safety data from the phase 3 IMvigor011 trial in patients with MIBC.

Dana-Farber Cancer Institute is Awarded $20 Million Grant From the Elaine and Eduardo Saverin Foundation

November 27, 2025

Article

Dana-Farber Cancer Institute was awarded a $20 million grant by The Elaine and Eduardo Saverin Foundation for advancements in metastatic breast cancer.

Five Under 5: Top Oncology Videos for the Week of 11/16

November 23, 2025

Article

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

Dr Bellmunt on Efficacy Findings With ctDNA-Guided Adjuvant Atezolizumab in MIBC

November 19, 2025

Video

Joaquim Bellmunt, MD, PhD, discusses the efficacy data seen with ctDNA-guided adjuvant atezolizumab in MIBC.

Neladalkib Proves Effective in TKI-Pretreated, Advanced ALK+ NSCLC

November 17, 2025

Article

Neladalkib elicited responses and was active in the CNS in TKI-pretreated patients with advanced ALK-positive NSCLC, including lorlatinib-naive patients.

New OncLive Podcast Series Launches With Focus on Gynecologic Oncology

November 17, 2025

Article

OncLive has launched a new podcast series, From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD.

Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis, MD; and Taymaa May, MD, MSc

November 13, 2025

Podcast

In the inaugural episode of this new podcast series, Drs Matulonis and May discuss advances in gynecologic cancer surgery.

Dr Bellmunt on the Design of the IMvigor011 Trial of ctDNA-Guided Adjuvant Atezolizumab in MIBC

November 12, 2025

Video

Joaquim Bellmunt, MD, PhD, discusses the phase 3 IMvigor011 trial of ctDNA-guided adjuvant atezolizumab in MIBC.

Immunotherapy Resistance in Kidney Cancer Driven by Myeloid Cell Signaling

November 12, 2025

Article

A study combined single-cell RNA sequencing data from patients with RCC to learn about patterns of interferon signaling across cell types in tumors.

Five Under 5: Top Oncology Videos for the Week of 11/2

November 09, 2025

Article

The top 5 OncLive TV videos of the week cover insights in breast cancer and ovarian cancer.

Dr Mayer on PRO Data With Camizestrant Plus CDK4/6 Inhibition in ESR1+ Breast Cancer

November 05, 2025

Video

Erica L. Mayer, MD, MPH, discussed PRO data in ESR1 mutation–emergent breast cancer following switch therapy to camizestrant plus a CDK4/6 inhibitor.

Dr Tarantino on the Efficacy of Neoadjuvant T-DXd/THP in High-Risk HER2+ Breast Cancer

November 05, 2025

Video

Paolo Tarantino, MD, PhD, discussed the clinical implications of the DESTINY-Breast11 trial of T-DXd/THP in high-risk, HER2-positive early breast cancer.

Dr Tolaney on the Efficacy of T-DXd in HER2+ Breast Cancer in the Post-Neoadjuvant Setting

November 05, 2025

Video

Sara M. Tolaney, MD, MPH, discussed the use of T-DXd in patients with HER2-positive breast cancer with residual disease after neoadjuvant therapy.

FDA Approves Menin Inhibitor for Patients With Acute Leukemia With NPM1 Mutation, Backed by Dana-Farber Science

November 04, 2025

Article

The US FDA approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and older with relapsed or refractory AML with NPM1 gene mutations.

Advances in EGFR+, HER2-Mutant, and CNS-Involved NSCLC Dominate Discussion After ESMO 2025

October 30, 2025

Article

Experts highlight pivotal data in EGFR- and HER2-mutant NSCLC from the 2025 ESMO Congress, including updates on ADCs, TKIs, and real-world outcomes in LMD.